Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886551627> ?p ?o ?g. }
- W2886551627 abstract "Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure-free, and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, sodium valproate and phenytoin are commonly used antiepileptic drugs for monotherapy treatment. It is generally believed that phenytoin is more effective for focal onset seizures, and that sodium pvalproate is more effective for generalised onset tonic-clonic seizures (with or without other generalised seizure types). This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons. This is the latest updated version of the review first published in 2001, and updated in 2013 and 2016.To review the time to treatment failure, remission and first seizure of sodium valproate compared to phenytoin when used as monotherapy in people with focal onset seizures or generalised tonic-clonic seizures (with or without other generalised seizure types).We searched the Cochrane Epilepsy Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform ICTRP on 19 February 2018. We handsearched relevant journals, contacted pharmaceutical companies, original trial investigators and experts in the field.Randomised controlled trials (RCTs) comparing monotherapy with either sodium valproate or phenytoin in children or adults with focal onset seizures or generalised onset tonic-clonic seizures DATA COLLECTION AND ANALYSIS: This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure and our secondary outcomes were time to first seizure post-randomisation, time to six-month, and 12-month remission, and incidence of adverse events. We used Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs) with 95% confidence intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.We included 11 trials in this review and IPD were available for 669 individuals out of 1119 eligible individuals from five out of 11 trials, 60% of the potential data. Results apply to focal onset seizures (simple, complex and secondary generalised tonic-clonic seizures), and generalised tonic-clonic seizures, but not other generalised seizure types (absence or myoclonus seizure types). For remission outcomes, a HR of less than 1 indicates an advantage for phenytoin, and for first seizure and treatment failure outcomes a HR of less than 1 indicates an advantage for sodium valproate.The main overall results were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type 0.88, 95% CI 0.61 to 1.27; 5 studies; 528 participants; moderate-quality evidence), time to treatment failure due to adverse events (pooled HR adjusted for seizure type 0.77, 95% CI 0.44 to 1.37; 4 studies; 418 participants; moderate-quality evidence), time to treatment failure due to lack of efficacy (pooled HR for all participants 1.16 (95% CI 0.71 to 1.89; 5 studies; 451 participants; moderate-quality evidence). These results suggest that treatment failure for any reason related to treatment and treatment failure due to adverse events may occur earlier on phenytoin compared to sodium valproate, while treatment failure due to lack of efficacy may occur earlier on sodium valproate than phenytoin; however none of these results were statistically significant.Results for time to first seizure (pooled HR adjusted for seizure type 1.08, 95% CI 0.88 to 1.33; 5 studies; 639 participants; low-quality evidence) suggest that first seizure recurrence may occur slightly earlier on sodium valproate compared to phenytoin. There were no clear differences between drugs in terms of time to 12-month remission (pooled HR adjusted for seizure type 1.02, 95% CI 0.81 to 1.28; 4 studies; 514 participants; moderate-quality evidence) and time to six-month remission (pooled HR adjusted for seizure type 1.05, 95% CI 0.86 to 1.27; 5 studies; 639 participants; moderate-quality evidence).Limited information was available regarding adverse events in the trials and we could not make comparisons between the rates of adverse events on sodium valproate and phenytoin. Some adverse events reported with both drugs were drowsiness, rash, dizziness, nausea and gastrointestinal problems. Weight gain was also reported with sodium valproate and gingival hypertrophy/hyperplasia was reported on phenytoin.The methodological quality of the included trials was generally good, however four out of the five trials providing IPD for analysis were of an open-label design, therefore all results were at risk of detection bias. There was also evidence that misclassification of seizure type may have confounded the results of this review, particularly for the outcome 'time to first seizure' and heterogeneity was present in analysis of treatment failure outcomes which could not be explained by subgroup analysis by epilepsy type or by sensitivity analysis for misclassification of seizure type. Therefore, for treatment failure outcomes we judged the quality of the evidence to be moderate to low, for 'time to first seizure' we judged the quality of the evidence to be low, and for remission outcomes we judged the quality of the evidence to be moderate.We have not found evidence that a significant difference exists between valproate and phenytoin for any of the outcomes examined in this review. However detection bias, classification bias and heterogeneity may have impacted on the results of this review. We did not find any outright evidence to support or refute current treatment policies. We recommend that future trials be designed to the highest quality possible with consideration of masking, choice of population, classification of seizure type, duration of follow-up, choice of outcomes and analysis, and presentation of results." @default.
- W2886551627 created "2018-08-22" @default.
- W2886551627 creator A5005069325 @default.
- W2886551627 creator A5017559586 @default.
- W2886551627 creator A5046267575 @default.
- W2886551627 creator A5083538395 @default.
- W2886551627 date "2018-08-09" @default.
- W2886551627 modified "2023-09-24" @default.
- W2886551627 title "Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review" @default.
- W2886551627 cites W1582940326 @default.
- W2886551627 cites W1895445482 @default.
- W2886551627 cites W1906001636 @default.
- W2886551627 cites W1917794385 @default.
- W2886551627 cites W1965295928 @default.
- W2886551627 cites W1967986271 @default.
- W2886551627 cites W1970901705 @default.
- W2886551627 cites W1971954813 @default.
- W2886551627 cites W1974489840 @default.
- W2886551627 cites W1974809694 @default.
- W2886551627 cites W1975584454 @default.
- W2886551627 cites W1979432994 @default.
- W2886551627 cites W1980415237 @default.
- W2886551627 cites W1994457839 @default.
- W2886551627 cites W1994572997 @default.
- W2886551627 cites W1996372964 @default.
- W2886551627 cites W1998651044 @default.
- W2886551627 cites W2002407252 @default.
- W2886551627 cites W2002808263 @default.
- W2886551627 cites W2014261444 @default.
- W2886551627 cites W2017422058 @default.
- W2886551627 cites W2022211892 @default.
- W2886551627 cites W2027759517 @default.
- W2886551627 cites W2031306229 @default.
- W2886551627 cites W2032677433 @default.
- W2886551627 cites W2035632263 @default.
- W2886551627 cites W2038413875 @default.
- W2886551627 cites W2039643007 @default.
- W2886551627 cites W2045274557 @default.
- W2886551627 cites W2046391772 @default.
- W2886551627 cites W2047200977 @default.
- W2886551627 cites W2049253299 @default.
- W2886551627 cites W2056985895 @default.
- W2886551627 cites W2058147010 @default.
- W2886551627 cites W2060159025 @default.
- W2886551627 cites W2060913012 @default.
- W2886551627 cites W2066410452 @default.
- W2886551627 cites W2069091142 @default.
- W2886551627 cites W2075642745 @default.
- W2886551627 cites W2075948811 @default.
- W2886551627 cites W2076472832 @default.
- W2886551627 cites W2076662133 @default.
- W2886551627 cites W2076993158 @default.
- W2886551627 cites W2082629538 @default.
- W2886551627 cites W2090175219 @default.
- W2886551627 cites W2092413298 @default.
- W2886551627 cites W2101614778 @default.
- W2886551627 cites W2103024352 @default.
- W2886551627 cites W2106277748 @default.
- W2886551627 cites W2108487427 @default.
- W2886551627 cites W2112034433 @default.
- W2886551627 cites W2114138473 @default.
- W2886551627 cites W2115247476 @default.
- W2886551627 cites W2116130425 @default.
- W2886551627 cites W2119186079 @default.
- W2886551627 cites W2119843181 @default.
- W2886551627 cites W2125435699 @default.
- W2886551627 cites W2136462495 @default.
- W2886551627 cites W2137936025 @default.
- W2886551627 cites W2139992285 @default.
- W2886551627 cites W2143309726 @default.
- W2886551627 cites W2146629358 @default.
- W2886551627 cites W2152985680 @default.
- W2886551627 cites W2156420184 @default.
- W2886551627 cites W2163597003 @default.
- W2886551627 cites W2166825256 @default.
- W2886551627 cites W2168075369 @default.
- W2886551627 cites W2281052180 @default.
- W2886551627 cites W2302029260 @default.
- W2886551627 cites W2313250813 @default.
- W2886551627 cites W2320058521 @default.
- W2886551627 cites W2326549167 @default.
- W2886551627 cites W2344760067 @default.
- W2886551627 cites W2399427256 @default.
- W2886551627 cites W2411333821 @default.
- W2886551627 cites W2414184925 @default.
- W2886551627 cites W2416443525 @default.
- W2886551627 cites W2417091214 @default.
- W2886551627 cites W2551860952 @default.
- W2886551627 cites W2592509339 @default.
- W2886551627 cites W2726071308 @default.
- W2886551627 cites W3166606476 @default.
- W2886551627 cites W4231112765 @default.
- W2886551627 cites W4236676256 @default.
- W2886551627 cites W4238361226 @default.
- W2886551627 cites W4239594659 @default.
- W2886551627 cites W4241136696 @default.
- W2886551627 cites W641823132 @default.
- W2886551627 doi "https://doi.org/10.1002/14651858.cd001769.pub4" @default.
- W2886551627 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6513104" @default.
- W2886551627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30091458" @default.